On 19 November 2014, orphan designation (EU/3/14/1358) was granted by the European Commission to FGK Representative Service GmbH, Germany, for recombinant human pentraxin-2 for the treatment of post-essential thrombocythaemia myelofibrosis.
The sponsorship was transferred to Roche Registration GmbH, Germany, in June 2020.
Recombinant human pentraxin-2
|Disease / condition||
Treatment of post-essential thrombocythaemia myelofibrosis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.